Glucorid 2 mg Tablet, manufactured by Biopharma Ltd., contains the generic Glimepiride. It is a sulfonylurea antidiabetic agent used as an adjunct to diet and exercise to lower blood glucose in patients with type II diabetes mellitus.
There are 41 brands of Glimepiride listed in Bangladesh. 15 of them have a lower unit price than Glucorid. The lowest listed price is Mepid 1 mg Tablet at ৳ 2.51 per unit.
What is Glucorid 2 mg Tablet?
Glucorid 2 mg Tablet is a prescription medicine from Biopharma Ltd. that contains Glimepiride, a sulfonylurea antidiabetic agent. It is used as an adjunct to diet and exercise to lower blood glucose in patients with non-insulin dependent (Type II) diabetes mellitus whose hyperglycaemia cannot be controlled by diet and exercise alone. It may also be used with metformin when diet, exercise, and Glimepiride or metformin alone do not provide adequate glycaemic control. The medicine works by stimulating the release of insulin from functioning pancreatic beta cells. The doctor decides the dose and course based on regular blood and urine glucose monitoring.
Uses of Glucorid
Glucorid 2 mg Tablet is used to lower blood glucose in adults with type II (non-insulin dependent) diabetes mellitus when diet and exercise alone are not enough. It can be prescribed alone or together with metformin when either medicine alone does not control blood sugar adequately. It is not for type I diabetes, diabetic ketoacidosis, or diabetic coma. Your doctor will determine if this medicine is suitable for you.
How to use Glucorid
Glucorid 2 mg Tablet is taken by mouth. The dose and how often you take it are decided by your doctor, who will set the lowest dose that controls your blood sugar. Your doctor will adjust the dose gradually based on regular blood and urine glucose tests. Do not change the dose yourself. Follow your doctor's instructions about diet and exercise, and ask your pharmacist if you have any questions about how to take it.
Side effects of Glucorid
Like all medicines, Glucorid 2 mg Tablet can cause side effects. The most important is hypoglycaemia (low blood sugar). Other possible side effects include temporary visual impairment, nausea, vomiting, diarrhoea, abdominal pain, urticaria, and a fall in blood pressure. If you experience symptoms of low blood sugar, take carbohydrates such as glucose or sugar immediately and contact your doctor. Report any side effects to your doctor or pharmacist.
Safety and precautions
Glucorid 2 mg Tablet is not suitable for people with type I diabetes, diabetic ketoacidosis, or diabetic coma. Do not take it if you are allergic to Glimepiride, other sulfonylureas, or sulfonamides, or if you have severe liver or kidney problems or are on dialysis. It must not be used during pregnancy or while breastfeeding; a changeover to insulin is necessary. Tell your doctor if you are planning a pregnancy or breastfeeding. In the first weeks of treatment, the risk of low blood sugar may be higher, so careful monitoring is needed. Ask your doctor or pharmacist before taking any other medicine, as interactions can occur.
Frequently asked questions
What is Glucorid 2 mg Tablet used for and what kind of medicine is it?
Glucorid 2 mg Tablet is a sulfonylurea antidiabetic medicine. It is used as an adjunct to diet and exercise to lower blood glucose in patients with type II diabetes mellitus whose hyperglycaemia cannot be controlled by diet and exercise alone. It may also be used with metformin.
How should Glucorid 2 mg Tablet be taken?
The dose and how often you take Glucorid 2 mg Tablet are decided by your doctor. The doctor will set the lowest dose that controls your blood sugar and adjust it gradually based on regular blood and urine glucose tests. Do not change the dose yourself.
What does the generic name Glimepiride mean?
Glimepiride is the generic name of the active ingredient in Glucorid 2 mg Tablet. It belongs to a group of medicines called sulfonylureas, which lower blood glucose by stimulating the release of insulin from the pancreas. The brand name Glucorid is made by Biopharma Ltd.
Glimepiride is indicated as an adjunct to diet and exercise to lower the blood glucose in patients with noninsulin dependent (Type II) diabetes mellitus (NIDDM) whose hyperglycaemia cannot be controlled by diet and exercise alone.
Glimepiride may be used concomitantly with metformin when diet, exercise, and Glimepiride or metformin alone does not result in adequate glycaemic control.
... Read more
Glimepiride is indicated in following conditions-
Glimepiride is indicated as an adjunct to diet and exercise to lower the blood glucose in patients with noninsulin dependent (Type II) diabetes mellitus (NIDDM) whose hyperglycaemia cannot be controlled by diet and exercise alone.
Glimepiride may be used concomitantly with metformin when diet, exercise, and Glimepiride or metformin alone does not result in adequate glycaemic control.
Glimepiride is also indicated for use in combination with insulin to lower blood glucose in patients whose hyperglycaemia cannot be controlled by diet and exercise in conjunction with an oral hypoglycaemic agent.
Combined use of Glimepiride and insulin may increase the potential for hypoglycaemia.
Pharmacology
Glimepiride is a sulfonylurea antidiabetic agent which decreases blood glucose concentration. The primary mechanism of action of Glimepiride appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells. Glimepiride acts in concert with glucose by improving the sensitivity of beta cells to physiological glucose stimulus, resulting in insulin secretion. In addition, extrapancreatic effects like reduction of basal hepatic glucose production, increased peripheral tissue sensitivity to insulin and glucose uptake may also play role in the activity of Glimepiride. In non-fasting diabetic patients, the hypoglycaemic action of a single dose of Glimepiride persists for 24 hours.
Dosage & Administration
In principle, the dosage of Glimepiride is governed by the desired blood sugar level. The dosage of Glimepiride must be the lowest which is sufficient to achieve the desired metabolic control. The initial and the maintenance doses are set based on the results of regular check of glucose in blood and urine. Monitoring of glucose levels in blood and urine also serves to detect either primary or secondary failure of therapy.
Initial dose and dose titration: the usual initial dose is 1 mg once daily, if necessary, the daily dose can be increased. Any increase can be based on regular blood sugar monitoring, and should be gradual, i.e., at intervals of 1 to 2 weeks, and carried out stepwise, as follows: 1 mg -> 2 mg -> 3 mg -> 4 mg -> 6 mg.
Dose in patients with well controlled diabetes: the usual dose range in patients with well controlled diabetes is 1 to 4 mg daily.
Distribution of doses: Timing and distribution of doses are decided by the physician, in consideration of the patient's current life-style. Normally, a single daily dose is sufficient. This should be taken immediately before a substantial breakfast or if none is taken immediately before the first main meal. It is very important not to skip meals after taking the drug.
Secondary dosage adjustment: As control of diabetes improves, sensitivity to insuiin increases; therefore, Glimepiride requirement may fall as treatment proceeds. To avoid hypoglycaemia, timely dose reduction or cessation of Glimepiride therapy must be considered. A dose adjustment must also be considered whenever the patient's weight or life-styie changes, or other factors arise which cause an increased susceptibility to hypo or hyperglycaemia.
Changeover from other oral antidiabetics to Glimepiride: There is no exact dosage relationship between Glimepiride and other oral blood sugar lowering agents. When substituting Glimepiride for other such agents, the initial daily dose is 1 mg; this applies even in changeover from maximum dose of other oral blood sugar lowering agents. Any dose increase should be in accordance with guideline given above in 'initial dose and dose titration'. Consideration must be given to the potency and duration of action of the previous blood sugar lowering agent. It may be necessary to interrupt treatment to avoid additive effects which would increase the risk of hypoglycaemia.
Interaction
Based on experience with Glimepiride and known interactions for other sulfonylureas, the following interactions must be considered.
In addition to insulin and other oral antidiabetic agents, drugs which may potentiate the hypoglycaemic action of Glimepiride include: ACE inhibitors, aminosalicylic acid, anabolic steroids and male sex hormones, azapropazone, chloramphenicol, ciofibrate, coumarin derivatives, cyclophosphamide, disopyramide, fenfluramine, fenyramidol, fibrates, fluconazole, fluoxetine, guanethidine, ifosfamide, MAO-inhibitors, miconazole, oxpentifylline (high dose parenteral), oxyphenbutazone, para-aminosalicylic acid, phenylbutazone, probenecid, quinolones, salicylates, sulphinpyrazone, sulfonamide antibiotics, tetracyclines, tritoqualine, trofosfamide.
Drugs which may attenuate the hypoglycaemic action of Glimepiride include:
H2 receptor antagonists, beta-blockers, clonidine and reserpine may lead to either potentiation or weakening of the blood-glucose-lowering effect.
Concomitant treatment with a beta-receptor blocker, clonidine, guanethidine or reserpine may mask the warning symptoms of a hypoglycaemic attack.
Acute and chronic aicohol intake may either potentiate or attenuate the activity of Glimepiride in an unpredictable fashion.
Contraindications
Glimepiride is not suitable for the treatment of insulin dependent (type I) diabetes mellitus, or for the treatment of diabetic ketoacidosis, nor for the treatment of diabetic coma. Glimepiride must not be used in patients hypersensitive to Glimepiride, other sulfonylureas, other sulfonamides, severe hepatic dysfunction, severe impairment of renal function and dialysis patients.
Side Effects
Hypoglycaemia, temporary visual impairment, nausea, vomiting, diarrhoea, abdominal pain, urticaria, fall in blood pressure.
Pregnancy & Lactation
Glimepiride must not be taken during pregnancy; a changeover to insulin is necessary. Patients planning a pregnancy must inform their physician, and should change over to insulin. Ingestion of Glimepiride with breast milk feeding may harm the child. Therefore, Glimepiride must not be taken by breastfeeding women. Either a changeover or complete discontinuation of breastfeeding is necessary.
Precautions & Warnings
in the initial weeks of treatment, the risk of hypoglycaemia may be increased and necessitates careful monitoring. If such risk present it may be necessary to adjust the dosage of Glimepiride, Hypoglycaemia can almost be promptly controlled by immediate intake of carbohydrates (glucose or sugar).
Overdose Effects
Overdosage of sulfonylureas, including Glimepiride, can produce hypoglycaemia. Mild hypoglycaemic symptoms without loss of consciousness or neurologic findings should be treated aggressively with oral glucose and adjustments in drug dosage or meal patterns. Close monitoring should continue until the physician is assured that the patient is out of danger. Severe hypoglycaemic reactions with coma, seizure, or other neurological impairment occur infrequently, but constitute medicai emergencies requiring immediate hospitalization. If hypoglycaemic coma is diagnosed or suspected, the patient should be given a rapid intravenous injection of concentrated (50%) glucose solution. This should be followed by a continuous infusion of a more dilute (10%) glucose solution at a rate that will maintain the blood glucose at a level above 100 mg/dl. Patients should be closely monitored for a minimum of 24 to 48 hours, because hypoglycaemia may recur after apparent clinical recovery.
Storage Conditions
Do not store above 30°C. Keep away from light and out of the reach of children.
Alternative brands of Glimepiride
Other brands with the same generic name, cheapest first.